Reportstack is one of the largest online libraries of market research publications. We are the fastest growing and most preferred provider of business intelligence in the market today. We partner with the world's top publishers and research houses to bring to you expert analysis, accurate data and market information along with the best customer support and user experience. For more details, please visit www.reportstack.com
Tuesday, 30 May 2017
Detailed Study of the China Procedure Numbers for Gynecological Devices
China Procedure Numbers for Gynecological Devices is a new market research publication announced by Reportstack.
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends • Market Drivers & Limiters for each chapter segment • Competitive Analysis for each chapter segment • Section on recent mergers & acquisitions Sales numbers are often sensationalized for mainland China. While China’s population is 1.38 billion, the working population (ages 15 to 64) is actually declining. Despite the removal of the One Child policy in 2016, are limiting the country’s growth. The assisted reproduction technology device market provides a well-informed, accurate forecast of procedure cycles and the changes to best practices affecting equipment sales. Understanding the effect of medical tourism also demonstrates the excess capacity and market potential in addition to the drivers and limiters motivating patients to travel for IVF treatments.
The gynecology market value is surprisingly stable, relative to the decreases evident in the global market. China has a cultural history of being cost-sensitive with a preference towards low to mid-end devices. While the shift to higher end devices in China is gradual, the change in purchase trends is causing stability in average sales prices that is unique globally. The high level of competition within China for manufacturers combined with quality changes is bolstering the overall market value beyond changes to unit sales.
The Made in China 2025 plan has identified the high frequency of unnecessary hospital visits within China. The role of a general practitioner as a first line of treatment is largely missing within China’s healthcare system. Attributable to both patient preference and physician salary, the view that hospitals offer superior medical care is prevalent throughout the country. The government is actively restructuring how patients seek medical care to create more physician practices. The expansion of general practices is leading to an increase of in-office medical procedures, and therefore an increase of sales for in-office capital equipment.
Astec Bio Casmed International Limited Cook Medical Cooper Surgical Esco Global Hunter Scientific Irvine Scientific Kitazato Life Global BRED Lifescience Technology Inc. Medi-Con International Merck KGaA - Genea Biomedx Nidacon Medical* Rocket Medical The Pipette Company Vitromed Vitrolife Karl Storz Olympus Johnson & Johnson Richard Wolf Stryker AngioDynamic Tonglu Zhouji Medical Instruments Co. Ltd China Carnation Endoscope Ltd. Merit Medical Systems Boston Scientific BTG "Medtronic (Smith & Nephew)" Pentax Aohua Hologic Carl Zeiss Kernel Colposcopes ARI Group Alltion Microscopes Co., Ltd. Wallach Surgical Edan Instruments Sunray Medical Coloplast Others include: Shenzhen Sinowares Co., Ltd., B-bridge International, Inc., Reproline Medical, Medtronic, Sigma-Aldrich China, CCD etc.